Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Combination therapy is increasingly becoming the cornerstone of current day antitumor
therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival …
therapy. Glioblastoma multiforme is an aggressive brain tumor with a dismal median survival …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Background Despite multimodality treatments including neurosurgery, radiotherapy and
chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered …
chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered …
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
C Cullinane, K Waldeck, L Kirby, BE Rogers, P Eu… - Scientific reports, 2020 - nature.com
Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
Biological mechanisms to reduce radioresistance and increase the efficacy of radiotherapy: state of the art
F Busato, BE Khouzai, M Mognato - International journal of molecular …, 2022 - mdpi.com
Cancer treatment with ionizing radiation (IR) is a well-established and effective clinical
method to fight different types of tumors and is a palliative treatment to cure metastatic …
method to fight different types of tumors and is a palliative treatment to cure metastatic …
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …
Combination strategies to improve targeted radionuclide therapy
In recent years, targeted radionuclide therapy (TRT) has emerged as a promising strategy
for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation …
for cancer treatment. In contrast to conventional radiotherapy, TRT delivers ionizing radiation …
Radioresistance of non-small cell lung cancers and therapeutic perspectives
M Césaire, J Montanari, H Curcio, D Lerouge… - Cancers, 2022 - mdpi.com
Simple Summary The poor survival of unresectable locally advanced stage non-small cell
lung cancer is due to the resistance to chemoradiotherapy and local/distant relapses …
lung cancer is due to the resistance to chemoradiotherapy and local/distant relapses …
PET imaging of PARP expression using 18F-olaparib
Poly (ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer
drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a …
drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a …